Local anaesthetic medication for the treatment of asthma

Siqueira, Rodrigo de Azeredo; Costa, Jorge; Cordeiro, Renato S.B.; Serra, Magda F.; Silva, Patrı́cia M.R. e; Martins, Marco A.

doi:10.1590/s0074-02762005000900027

Cited by 7 publications

(5 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The mechanism of this improvement is likely multifactorial. As described by Serra et al and Siqueira et al , our patient likely benefitted from a decrease in bronchial hyperreactivity and inflammatory mediators as well as decreased propagation of reflex transmissions 7 9. Overall, this led to a stable anaesthetic course with no complications.…”

Section: Discussionsupporting

confidence: 72%

Addition of nebulised lidocaine to prevent refractory bronchospasms in a patient receiving serial bronchoscopies

Grell

2023

BMJ Case Rep

View full text Add to dashboard Cite

A patient in his 20s with a history of granulomatosis with polyangiitis required 15 bronchoscopies with dilations in 1 year due to bronchial fibrosis and secretions leading to worsening shortness of breath. During these bronchoscopies, the patient experienced increasingly severe bronchospasms refractory to conventional preventative and treatment methodologies leading to prolonged hypoxia, reintubations and ICU admissions. During his 8th to 15th bronchoscopies, nebulised lidocaine was added to the pretreatment regimen, which eliminated perioperative bronchospasms and allowed for the elimination of all other adjunctive preventative treatments. This case highlights the novel perioperative use of nebulised lidocaine, in combination with nebulised albuterol and intravenous hydrocortisone, to successfully prevent previously refractory bronchospasms in a patient undergoing a general anaesthetic.

show abstract

Section: Discussionsupporting

confidence: 72%

Addition of nebulised lidocaine to prevent refractory bronchospasms in a patient receiving serial bronchoscopies

Grell

2023

BMJ Case Rep

View full text Add to dashboard Cite

show abstract

“…Asthma is a chronic inflammatory condition, triggered by environmental factors in genetically predisposed individuals [Siqueira et al, 2005]. It is characterized by mast cell, T lymphocyte, and eosinophil infiltrates in the bronchial mucosa [Roquet et al, 1997].…”

Section: Introductionmentioning

confidence: 99%

Cell screening assay for identifying inhibitors of eosinophil proliferation

Kempe-Dustin

Aboul‐Fadl

Christensen

et al. 2011

Drug Development Research

View full text Add to dashboard Cite

The purpose of this study was to develop a cell-based screening assay for identification of small molecules for the treatment of asthma. Eosinophils are leukocytes that contribute to the pathology of asthma. Lidocaine inhibits interleukin-5 (IL-5)-mediated survival and activation of human eosinophils, and it is able to replace inhaled glucocorticoids for the treatment of asthma; however, lidocaine has many side effects, including anesthesia. Therefore, a collection of commercial and novel, synthesized lidocaine analogues were investigated for inhibitory activity of the IL-5-stimulated proliferation of TF-1 cells, a CD34 1 , cytokine-dependent, erythroleukemic cell line model for eosinophil growth. Among 74 investigated compounds, 10 were more potent inhibitors of cell proliferation than lidocaine (average IC 50 5 223 mM), with IC 50 values ranging within 1-119 mM. This cell-based assay is an effective method for screening chemical compounds and has revealed promising lead compounds for the treatment of asthma. Drug Dev Res 72: 353-360, 2011.

show abstract

“…[ 10 ] It has been observed that inhaled lignocaine has glucocorticosteroid-sparing properties in atopic asthmatics as demonstrated by a significant reduction in symptoms, bronchodilator use, and blood eosinophilia. [ 11 ] In the present study, we have studied the effect of inhalational lignocaine on oxygen saturation and the requirement of oxygen following treatment. Findings corroborated the efficacy in such patients in terms of improvement in oxygenation and reduced requirement of oxygen therapy.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of lignocaine nebulization in patients with COVID-19 respiratory infection: An exploratory randomized double-blinded controlled trial

Talawar,

Tripathy,

Kaushal

et al. 2024

Journal of Anaesthesiology Clinical Pharmacology

View full text Add to dashboard Cite

Background and Aims: Coronavirus disease (COVID-19)-related pneumonia is proposed to be an inflammatory process. The treatment currently includes supportive therapy and low-dose steroids. Anti-inflammatory drugs have been proposed to prevent cytokine storms and improve oxygenation in such cases. The study aimed to assess the efficacy of nebulized lignocaine in COVID-19 patients with pneumonia. Material and Methods: This was an exploratory randomized double-blinded control trial conducted in COVID-19 patients with respiratory failure requiring oxygen therapy either by face mask or non-invasive mechanical ventilation. Patients included were of the age of more than 18 years of either gender. The patients were randomized to receive either lignocaine or distilled water nebulization. The outcomes assessed were PaO2/FiO2 ratio, hemodynamics, respiratory parameters, and sequential organ failure score (SOFA). Results: The two groups were comparable concerning demographic variables. The PaO2/FiO2 were significantly higher in the lignocaine group from day 2 onward. The SPO2 was significantly higher on day 3 in the lignocaine group and thereafter there was no significant difference. Other hemodynamic, respiratory parameters, and SOFA scores showed no difference in both the groups. Conclusion: Lignocaine nebulization improved oxygenation in COVID-19 patients and can be used as adjunctive therapy along with other supportive medications.

show abstract

Local anaesthetic medication for the treatment of asthma

Cited by 7 publications

References 41 publications

Addition of nebulised lidocaine to prevent refractory bronchospasms in a patient receiving serial bronchoscopies

Addition of nebulised lidocaine to prevent refractory bronchospasms in a patient receiving serial bronchoscopies

Cell screening assay for identifying inhibitors of eosinophil proliferation

Efficacy of lignocaine nebulization in patients with COVID-19 respiratory infection: An exploratory randomized double-blinded controlled trial

Contact Info

Product

Resources

About